FluoGuide Management

Management criteria checks 1/4

FluoGuide's CEO is Morten Albrechtsen, appointed in Jan 2018, has a tenure of 6.25 years. directly owns 12.2% of the company’s shares, worth €6.22M. The average tenure of the management team and the board of directors is 4.8 years and 2 years respectively.

Key information

Morten Albrechtsen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.3yrs
CEO ownership	12.2%
Management average tenure	4.8yrs
Board average tenure	2yrs

Recent management updates

Recent updates

CEO

Morten Albrechtsen (59 yo)

6.3yrs

Tenure

Mr. Morten Albrechtsen, M.D., BBA, has been the CEO at Fluoguide A/s since 2018. He is the Co-founder and serves as the Chief Executive Officer at radiotherapy specialists Nanovi ApS. Mr. Albrechtsen Found...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Morten Albrechtsen	Chief Executive Officer	6.3yrs	no data	12.2% DKK 6.2m
Ole Larsen	Chief Financial Officer	1.2yrs	no data	no data
Andreas Kjaer	CSO, CMO	no data	no data	17.43% DKK 8.9m
Grethe Rasmussen	Chief Development Officer	5.3yrs	no data	3.06% DKK 1.6m
Dorthe Mejer	Vice President of Clinical Development	4.3yrs	no data	0.0059% DKK 3.0k

4.8yrs

Average Tenure

59.5yo

Average Age

Experienced Management: 96X's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andreas Kjaer	CSO, CMO	6.3yrs	no data	17.43% DKK 8.9m
Mats Thoren	Vice Chairman of the Board	2.8yrs	no data	0.010% DKK 5.1k
Donna Haire	Director	less than a year	no data	no data
Peter Eriksen	Independent Chairman	5.3yrs	no data	0.96% DKK 490.3k
Michael Engsig	Independent Director	1.1yrs	no data	no data
Roger Gunnarsson	Director	less than a year	no data	no data

2.0yrs

Average Tenure

54yo

Average Age

Experienced Board: 96X's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

FluoGuide Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide Announces CFO Changes

Recent updates

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

Forecast to breakeven in 2025

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Forecast to breakeven in 2024

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

Forecast to breakeven in 2024

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age